Brand Name
Danogen Forte
Generic Name / Composition
Danazol 200 mg
(Some brands of Danogen Forte are also available in 200 mg and 400 mg strength — confirm pack strength while dispensing)
Main Category
-
Synthetic Androgen / Antigonadotropic Agent
(Hormonal therapy – gynecological & hematological use)
Uses / Indications
-
Gynecological Conditions
-
Endometriosis (relieves pelvic pain, suppresses endometrial tissue growth)
-
Fibrocystic breast disease (benign breast pain & nodularity)
-
Menorrhagia (off-label use for heavy menstrual bleeding)
-
-
Hematological / Immunological Disorders
-
Hereditary angioedema (to prevent swelling attacks)
-
Sometimes used in idiopathic thrombocytopenic purpura (ITP) – specialist guidance only
-
Dosage (General Guidance)
(As per physician’s direction)
-
Endometriosis: 200–800 mg/day in divided doses for 3–6 months
-
Fibrocystic breast disease: 100–400 mg/day in divided doses
-
Hereditary angioedema: 200 mg two to three times daily initially, then maintenance 200 mg/day
Route: Oral
Side Effects
-
Weight gain, acne, oily skin
-
Hoarseness or deepening of voice (may be permanent)
-
Hirsutism (unwanted hair growth)
-
Menstrual disturbances (amenorrhea, irregular cycles)
-
Mood changes, headache
-
Rare: Liver dysfunction, thromboembolic events
Precautions / Warnings
-
Contraindicated in pregnancy, breastfeeding, severe liver/kidney/heart disease, androgen-dependent tumors
-
May cause virilization in women (monitor for voice changes, hair growth)
-
Long-term therapy requires monitoring of liver function & lipid profile
-
Use with caution in diabetic patients (may alter blood sugar control)
-
Not recommended in children except in hereditary angioedema under specialist supervision
Drug Interactions
-
Warfarin (↑ anticoagulant effect, bleeding risk)
-
Carbamazepine, Cyclosporine, Statins (↑ toxicity)
-
Insulin / oral antidiabetic agents (may affect glucose control)
Packaging
-
Strip of 10 capsules (commonly 200 mg strength; Forte version often denotes higher dose)
Reviews
There are no reviews yet.